1 day Ago By ABMN Staff
Legal & General Group Plc lifted its holdings in Capricor Therapeutics Inc ( NASDAQ:CAPR – Free Report ) by 1,029.7% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 30,783 shares of the biotechnology company’s stock after purchasing an additional 28,058 shares during the period.
Legal & General Group Plc’s holdings in Capricor Therapeutics were worth $425,000 at the end of the most recent reporting period. Several other large investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc.
grew its stake in shares of Capricor Therapeutics by 44.4% in the fourth quarter. Vanguard Group Inc.
now owns 2,276,784 shares of the biotechnology company’s stock worth $31,420,000 after acquiring an additional 700,243 shares in the last quarter. Black Diamond Financial LLC acquired a new position in Capricor Therapeutics during the 4th quarter worth $3,833,000. Geode Capital Management LLC increased its holdings in Capricor Therapeutics by 37.
8% during the 4th quarter. Geode Capital Management LLC now owns 879,468 shares of the biotechnology company’s stock worth $12,139,000 after purchasing an additional 241,279 shares during the period. Swiss National Bank acquired a new stake in Capricor Therapeutics in the 4th quarter valued at about $930,000.
Finally, JPMorgan Chase & Co. boosted its stake in shares of Capricor Therapeutics by 419.5% in the 3rd quarter.
JPMorgan Chase & Co. now owns 56,199 shares of the biotechnology company’s stock valued at $855,000 after buying an additional 45,381 shares during the period. 21.
68% of the stock is owned by hedge funds and other institutional investors. Analyst Upgrades and Downgrades Several brokerages recently weighed in on CAPR. HC Wainwright reaffirmed a “buy” rating and issued a $77.
00 target price on shares of Capricor Therapeutics in a report on Monday, March 17th. Cantor Fitzgerald reissued an “overweight” rating and set a $30.00 target price on shares of Capricor Therapeutics in a research report on Thursday, March 20th.
One analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to MarketBeat, Capricor Therapeutics has an average rating of “Moderate Buy” and an average price target of $34.50.
Capricor Therapeutics Price Performance Shares of NASDAQ CAPR opened at $12.56 on Wednesday. Capricor Therapeutics Inc has a 1-year low of $3.
52 and a 1-year high of $23.40. The company has a market cap of $573.
70 million, a PE ratio of -11.85 and a beta of 4.65.
The stock has a fifty day moving average price of $11.99 and a 200 day moving average price of $14.78.
Capricor Therapeutics ( NASDAQ:CAPR – Get Free Report ) last posted its quarterly earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.
31) by $0.15. Capricor Therapeutics had a negative net margin of 146.
86% and a negative return on equity of 112.95%. The firm had revenue of $11.
13 million during the quarter, compared to analysts’ expectations of $9.87 million. Analysts anticipate that Capricor Therapeutics Inc will post -1.
21 earnings per share for the current fiscal year. About Capricor Therapeutics ( Free Report ) Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Read More Want to see what other hedge funds are holding CAPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Capricor Therapeutics Inc ( NASDAQ:CAPR – Free Report ). Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
